Prevalence and Clinical Relevance of Antiphospholipid Antibodies in Ischemic Stroke: A Systematic Review and Meta-Analysis.

StrokeAug 28, 2026 (epub)
Clinical ResearchHematologyNeurologyOpen access

Nathan W Watson, Syed Bukhari, Sina Rashedi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the prevalence of antiphospholipid antibodies (aPL) in patients with ischemic stroke. Among 9438 patients, the pooled prevalence of aPL seropositivity was 19.1%. The analysis revealed that aPL seropositivity was associated with increased odds of first ischemic stroke (OR, 2.93), particularly for lupus anticoagulant (OR, 6.69).

Key findings

  • Pooled prevalence of aPL seropositivity in ischemic stroke patients was 19.1%.
  • aPL seropositivity increased the odds of first ischemic stroke (OR, 2.93).
  • Lupus anticoagulant showed the strongest association with first ischemic stroke (OR, 6.69).
  • No significant difference in recurrent ischemic stroke odds with aPL seropositivity (OR, 1.20).

Why it matters

Understanding the prevalence and implications of aPL seropositivity in ischemic stroke patients can aid clinicians in risk assessment and management strategies for stroke prevention.

Source

PubMed · PMID 42663055Free full text on PubMed Central

Published in Stroke. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.